Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Andreozzi, Giuseppe Maria; Bignamini, Angelo; Davı̀, Giovanni

doi:10.1016/j.jvsv.2016.06.012

Cited by 38 publications

(52 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sulodexide reduced the risk of recurrence by ∼50% with no apparent increase in bleeding events. However, only 8% of patients in this study had PE as the index VTE event [357].…”

Section: Anticoagulant-related Bleeding Riskmentioning

confidence: 60%

“…A randomized, placebo controlled study evaluated sulodexide (2×250 lipasemic unit capsules b.i.d.) for the prevention of recurrence in 615 patients with a first VTE event without an identifiable risk factor, who had completed 3-12 months of oral anticoagulant treatment (supplementary table 15) [357]. Sulodexide reduced the risk of recurrence by ∼50% with no apparent increase in bleeding events.…”

Section: Anticoagulant-related Bleeding Riskmentioning

confidence: 99%

“…In patients who refuse to take or are unable to tolerate any form of oral anticoagulants, aspirin or sulodexide may be considered for extended VTE prophylaxis [355][356][357].…”

Section: Extended Treatment With Alternative Antithrombotic Agentsmentioning

confidence: 99%

See 2 more Smart Citations

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Sulodexide reduced the risk of recurrence by ∼50% with no apparent increase in bleeding events. However, only 8% of patients in this study had PE as the index VTE event [357].…”

Section: Anticoagulant-related Bleeding Riskmentioning

confidence: 60%

Section: Anticoagulant-related Bleeding Riskmentioning

confidence: 99%

See 1 more Smart Citation

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Амбулаторно контроль за уровнем МНО осуществлялся в поликлинике по месту жительства в течение года с коррекцией дозы варфарина до оптимальных значений 2,0-3,0. Во второй группе перевод больных на СД осуществлялся амбулаторно через 2,5-3,0 месяца от начала лечения проксимального ТГВНК [14]. Показаниями для назначения СД являлись невозможность приема и передозировка АВК, отсутствие реканализации на фоне приема АВК и сохраняющийся отечно-болевой синдром, нарушение в системе протеина С, снижение антитромбина III и развитие тромбоцитопении, угнетение фибринолиза.…”

Section: материалы и методыunclassified

“…В последние годы в клинической практике распространение получили таблетированные антитромботические средства, в частности гепариноиды, влияющие на эндотелий сосудистой стенки и систему гемостаза, способные корригировать процессы микроциркуляции на тканевом уровне. Среди них большой интерес представляет сулодексид (Вессел Дуэ Ф) (СД), который обладает антикоагулянтным действием за счет сродства к кофактору II гепарина и подавлением активированного X фактора, усилением синтеза и секреции простациклина (ПГI2) и снижением уровня фибриногена в плазме крови [12][13][14].…”

Section: Introductionunclassified

The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs

Petrikov

Dudin

Зайцев

et al. 2018

Stacionarozameshchayushchie tekhnologii: Ambulatornaya khirurgi

View full text Add to dashboard Cite

The article is devoted to the incidence and severity of post-thrombotic syndrome (PTS), the odds ratio (OR) of PTS development in patients with previous proximal deep vein thrombosis (DVT) against the background of prolonged antithrombotic warfarin and sulodexide (SD) therapy (ATT) with due account for safety and development of clinically significant bleeding (CSB) during the year. A total of 130 patients aged 18 to 69 years with acute proximal DVT were enrolled in the comparative prospective study. Group I included 64 patients (31 men and 33 women), who received vitamin K antagonists (warfarin) therapy. Group II included 66 patients (37 men and 29 women), who received sulodexide in 3 months after completing a course of standard ACT (heparins in the acute period with the transition to AVK). The studied parameters included OR, incidence and severity of PTS in patients according to the Villalta scale, and the incidence rate of PTS against the background of prolonged warfarin and sulodexide ATT in 12 months’ time. It was established that the prolonged sulodexide ATT within one year after completing a course of standard ACT in patients with proximal DVT reduced the development of clinical signs of PTS by 22.2% compared to the standard warfarin therapy. At the same time, there is a lower incidence of severe forms of PTS in patients, who underwent proximal venous thrombosis, 17.8% against the background of sulodexide treatment. Thus, the prolonged sulodexide ATT is associated with a 1.7-fold decrease in the risk of the development of both PTS and its severe forms. Therefore, the prolonged use of sulodexide for one year in patients, who underwent proximal DVT, provides an alternative to warfarin and is associated with a lower incidence of PTS, including its severe forms. The prolonged sulodexide ATT is safe and does not cause the development of clinically significant hemorrhagic complications during the year.

show abstract

Chronic venous disease – Part I: Inflammatory biomarkers in wound healing

Ligi

Mosti²,

Croce

et al. 2016

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

Venous leg ulcers (VLUs) produce wound fluid (WF), as a result of inflammatory processes within the wound. It is unclear if WF from different healing phases of VLU has a peculiar biochemical profile and how VLU microenvironment affects the wound healing mechanisms. This study was conducted to evaluate the cytokine/chemokine profiles in WF from distinct VLU phases, in WF- and LPS-stimulated monocytes and treated with glycosaminoglycan Sulodexide, a therapeutic option for VLU healing. WF and plasma were collected from patients with VLU during active inflammatory (Infl) and granulating (Gran) phases. Demographics, clinical characteristics and pain measurements were evaluated. WF, plasma, and THP-1 supernatants were analyzed for 27 inflammatory mediators by multiplex immunoassay. Our results demonstrated that: 1) pain was significantly increased in patients with Infl compared to Gran VLU; 2) cytokine profile of Infl WF was found to be statistically different from that Gran WF, as well significantly increased respect to plasma; 3) LPS- and WF-stimulation of THP-1 cells significantly increased the expression of several cytokines compared to untreated cells; 4) Sulodexide treatment of both LPS- and WF-stimulated THP-1 monocytes was able to significantly down-regulate the release of peculiar inflammatory mediators. Our study highlighted the importance to understand biomolecular processes underlying CVI when providing treatment for chronic VLU. Identification of inflammatory biomarkers in leg ulcer microenvironment, may provide useful tools for predicting healing outcome and developing targeted therapies.

show abstract

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Cited by 38 publications

References 20 publications

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs

Chronic venous disease – Part I: Inflammatory biomarkers in wound healing

Contact Info

Product

Resources

About